More patients are asking therapists and medical providers whether ketamine therapy could help with depression, trauma, anxiety, or treatment-resistant symptoms. Some arrive with detailed questions, while others simply ask, “Could this help me?”
For clinicians without formal ketamine-assisted psychotherapy training, these conversations can feel difficult to navigate. You may be curious about the clinical possibilities but unsure about safety, treatment models, patient suitability, professional scope, referrals, or the role of psychotherapy.
Curiosity is a responsible place to begin. You do not need every answer, but you do need a reliable framework for learning, recognising the limits of your knowledge, and helping patients make informed decisions about their available treatment options.
Why More Providers Are Becoming Curious About Ketamine Therapy
Ketamine therapy is becoming increasingly visible within conversations about mental health treatment.
Patients who have spent years trying psychotherapy, psychiatric medication, lifestyle changes, and other interventions may be looking for additional options. They may be experiencing treatment-resistant symptoms, recurring emotional patterns, trauma-related difficulties, or a persistent feeling of being stuck.
As awareness grows, clinicians are more likely to encounter questions such as:
- What is ketamine therapy?
- Is ketamine the same as Spravato?
- What happens during a ketamine session?
- Is psychotherapy included?
- Who decides whether someone is medically eligible?
- Can I continue working with my current therapist?
- How do I find a reputable provider?
- Could ketamine help when traditional therapy has not been enough?
Providers do not need to promote ketamine therapy or present it as the right option for every patient. However, being able to respond thoughtfully is becoming an increasingly relevant part of clinical care.
A grounded response may begin with acknowledging the patient’s interest, exploring what they are hoping treatment will change, and helping them understand that “ketamine therapy” can refer to several different treatment approaches.
Curiosity Is a Good Place to Begin
One of the biggest barriers for clinicians entering the ketamine field is the belief that they must become experts before joining the conversation. That is not the case.
Many therapists, psychiatric providers, nurses, physicians, and clinicians are developing their understanding of ketamine treatment. The field brings together medical assessment, medication administration, psychological preparation, altered states of consciousness, therapeutic support, integration, ethics, and interdisciplinary collaboration.
It is natural for clinicians to understand some areas more deeply than others. A therapist may feel confident supporting trauma processing and integration but know less about dosing, screening, or cardiovascular risk. A medical provider may understand pharmacology, contraindications, and monitoring while having less experience preparing patients psychologically or supporting meaning-making after treatment.
Responsible ketamine care depends on recognising the boundaries of each professional role and knowing when collaboration is needed.
The Ko-Op was developed around accessibility, safety, education, and collaboration. Its clinician-focused services include KAP training, workshops, practice resources, and support for therapists who want to explore this work responsibly.
For clinicians at the beginning, the first goal does not need to be offering KAP. It can simply be learning the landscape, asking better questions, and understanding where your skills may fit within collaborative care.
Understanding the Different Ketamine Treatment Models
The term “ketamine therapy” does not describe one standardised experience.
Patients may encounter several delivery methods and clinical models, including IV ketamine, intramuscular ketamine, Spravato, sublingual or oral ketamine, and ketamine-assisted psychotherapy.
These approaches can differ in how the medicine is administered, where treatment takes place, who supervises it, whether psychotherapy is included, and what happens before and after the medicine session.
IV ketamine
Intravenous ketamine is administered through an IV, generally in a medical setting where the patient can be monitored. The dose can be controlled throughout the infusion.
Some IV clinics primarily focus on the biological or antidepressant effects of ketamine. Others may work collaboratively with psychotherapists or offer additional psychological support.
IM ketamine
Intramuscular ketamine is administered through an injection. It may be used within medical or ketamine-assisted psychotherapy settings, depending on the provider and treatment model.
The psychological experience may be an important part of the session, particularly when IM ketamine is delivered as part of a broader therapeutic process.
Spravato
Spravato is the brand name for esketamine, which is administered as a nasal spray within an approved clinical setting.
Although patients may use the terms Spravato and ketamine interchangeably, they are not identical treatment models. Providers beginning their education should understand how esketamine treatment differs from other forms of ketamine administration and how psychotherapy may or may not be incorporated.
Sublingual or oral ketamine
Sublingual ketamine is often provided as a lozenge or tablet that dissolves in the mouth. Oral and sublingual treatment models may take place in a clinic or, in some programmes, at home under an established medical protocol.
The level of therapeutic support can vary considerably. Some patients may receive medication management alone, while others may participate in preparation, medicine sessions, and integration with a therapist.
Ketamine-assisted psychotherapy
Ketamine-assisted psychotherapy, or KAP, intentionally combines the ketamine experience with psychotherapy.
The medicine is not treated as the entire intervention. Instead, preparation, the therapeutic relationship, the medicine experience, and integration are viewed as connected parts of the process.
The Ko-Op describes KAP as a tool for clients who are struggling with treatment-resistant symptoms, stuck points, and repetitive life patterns. Its approach emphasises safe access, medical screening, therapeutic support, and education for both clients and clinicians.
Understanding these distinctions helps providers avoid speaking about ketamine therapy as though every patient receives the same treatment.
Medical Providers Need Clear Clinical Frameworks
Interest in ketamine should be supported by careful clinical thinking.
A provider does not need to independently determine whether ketamine is appropriate for a patient unless that decision falls within their professional role. However, all clinicians involved in the patient’s care benefit from understanding the questions that responsible ketamine providers should be asking.
These may include:
- What symptoms is the patient hoping to address?
- What treatments have already been attempted?
- Is the patient medically and psychologically appropriate for treatment?
- Are there current safety concerns?
- Who is responsible for screening and prescribing?
- How will the patient be monitored?
- What preparation is offered before treatment?
- What support is available during the ketamine experience?
- How will integration be handled afterwards?
- How will the ketamine provider communicate with the patient’s existing treatment team?
- What happens if the patient becomes distressed or clinically unstable?
These questions help providers look beyond marketing language and evaluate the actual structure of care.
A reputable referral should involve more than confirming that a clinic provides ketamine. Providers should also understand what type of ketamine is offered, who conducts the medical evaluation, whether therapy is included, how emergencies are handled, and what communication is available between professionals.
The Therapist’s Role May Begin Before KAP Training
Therapists who are not yet trained in KAP can still play an important role when clients ask about ketamine.
That role may include helping the client clarify their expectations, explore their motivations, identify fears, recognise unrealistic assumptions, and prepare questions for a medical provider.
For example, a client may believe ketamine will immediately remove painful memories or permanently resolve depression after one session. A therapist can help the client approach treatment with more realistic expectations without presenting themselves as a ketamine expert.
Therapists can also support clients in thinking about what they want from treatment beyond symptom relief.
What would meaningful change look like? What patterns feel stuck? What emotional material might arise? What support will the client need afterwards? How might insights from the experience be translated into daily life?
These conversations are closely connected to the existing skills many therapists already use.
However, clinicians should be careful not to move beyond their training or scope. General therapeutic support is different from presenting oneself as a KAP provider, guiding a medicine session, or giving medical advice.
Learning where that distinction lies is part of becoming more clinically responsible.
Learning Is Easier in Community
Ketamine is an evolving and interdisciplinary field. It can be difficult to understand through isolated articles, social media posts, or promotional materials alone. Consultation gives clinicians a place to slow down and think.
Instead of only asking, “How do I offer KAP?” providers can explore more foundational questions:
- What does responsible collaboration look like?
- How do I discuss ketamine without overpromising?
- When should I refer a patient for a medical evaluation?
- How can I assess whether a programme offers adequate psychological support?
- What is the difference between preparation and integration?
- How do medical and psychotherapeutic providers communicate?
- What ethical concerns should therapists consider?
- What additional training would I need before becoming directly involved?
A consultation community also gives clinicians an opportunity to learn from the experiences of others.
A therapist may raise a question about boundaries during an altered state. A nurse practitioner may explain what information is needed during medical screening. A KAP-trained clinician may discuss how preparation affects the medicine session. Another provider may share how they coordinate care while maintaining clear professional roles.
These discussions help turn abstract information into practical clinical understanding. They also reduce the pressure to learn everything alone.
You Do Not Need to Decide Your Final Role Yet
Some clinicians begin learning about ketamine because they want to become KAP providers. Others want to support existing clients who are receiving treatment elsewhere. Some want to develop referral relationships, while others simply want to answer patient questions more accurately.
You do not need to know which path you will ultimately take before you begin.
Your starting point may be:
- Learning the differences between ketamine treatment models
- Understanding preparation and integration
- Observing how KAP sessions are structured
- Joining professional consultations
- Receiving formal KAP training
- Building relationships with reputable medical providers
- Reviewing ethical and legal considerations
- Learning how to speak with patients about referrals
- Exploring whether KAP aligns with your clinical approach
Beginning with education allows your eventual role to develop thoughtfully rather than reactively.
A Thoughtful Place to Start
Patients are already bringing questions about ketamine into therapy rooms, medical practices, and psychiatric appointments.
Providers do not need to have every answer. They do need places where they can ask questions, consider clinical responsibilities, learn the differences between treatment models, and better understand how medical and psychotherapeutic care can work together.
The Ko-Op community and consultation group is designed for therapists and medical providers who are beginning to learn about ketamine therapy and want a thoughtful, clinically responsible place to start.
Whether you are considering formal KAP training, supporting a patient who is exploring ketamine treatment, or simply trying to understand the field more clearly, community-based learning can help you move from curiosity to informed clinical understanding.
Join the Ko-Op community to learn alongside other providers, bring your questions into consultation, and begin exploring ketamine-assisted care with greater clarity, responsibility, and support.
Frequently Asked Questions
Q. Do therapists need formal KAP training to discuss ketamine with clients?
Therapists do not need formal KAP training to acknowledge a client’s interest, explore their expectations, or help them prepare questions. However, they should remain within their scope and avoid providing medical advice or presenting themselves as KAP providers.
Q. What types of ketamine treatment should providers understand?
Providers may encounter IV ketamine, IM ketamine, Spravato, sublingual or oral ketamine, and ketamine-assisted psychotherapy. Each model differs in administration, supervision, setting, psychological support, and the role of preparation and integration.
Q. How can providers identify a reputable ketamine referral option?
Providers should ask who completes the medical screening, how patients are monitored, what type of ketamine is offered, whether psychotherapy is included, how emergencies are managed, and how the ketamine provider communicates with the patient’s existing care team.
Q. How can the Ko-Op community help providers beginning to learn about KAP?
The Ko-Op community gives therapists and medical providers a place to ask questions, discuss clinical considerations, understand professional roles, and learn how medical and psychotherapeutic providers can collaborate responsibly within ketamine-assisted care.
